Reviva Pharmaceuticals Holdings Future Growth

Future criteria checks 0/6

Reviva Pharmaceuticals Holdings is forecast to grow earnings and revenue by 42.2% and 67.4% per annum respectively while EPS is expected to grow by 49.1% per annum.

Key information

42.2%

Earnings growth rate

49.1%

EPS growth rate

Pharmaceuticals earnings growth	19.8%
Revenue growth rate	67.4%
Future return on equity	n/a
Analyst coverage	Good
Last updated	10 Jan 2025

Recent future growth updates

Recent updates

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Dec 11

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Aug 24

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Dec 28

Reviva Pharmaceuticals drops 9% on $8.5M private placement

Sep 06

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Aug 24

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Aug 15

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Apr 26

Earnings and Revenue Growth Forecasts

NasdaqCM:RVPH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	N/A	-46	-52	-52	3
12/31/2026	N/A	-40	-41	-41	4
12/31/2025	N/A	-41	-36	-38	6
12/31/2024	N/A	-32	-34	-32	6
9/30/2024	N/A	-33	-33	-33	N/A
6/30/2024	N/A	-36	-35	-35	N/A
3/31/2024	N/A	-40	-32	-32	N/A
12/31/2023	N/A	-39	-28	-28	N/A
9/30/2023	N/A	-42	-24	-24	N/A
6/30/2023	N/A	-34	-22	-22	N/A
3/31/2023	N/A	-28	-21	-21	N/A
12/31/2022	N/A	-28	-19	-19	N/A
9/30/2022	N/A	-20	-18	-18	N/A
6/30/2022	N/A	-19	-16	-16	N/A
3/31/2022	N/A	-15	-14	-14	N/A
12/31/2021	N/A	-9	-11	-11	N/A
9/30/2021	N/A	-6	-10	-10	N/A
6/30/2021	N/A	-5	-8	-8	N/A
3/31/2021	N/A	-4	-7	-7	N/A
12/31/2020	N/A	-4	-4	-4	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	0	0	N/A
3/31/2020	N/A	-1	0	0	N/A
12/31/2019	N/A	-1	0	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RVPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RVPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RVPH is forecast to have no revenue next year.

High Growth Revenue: RVPH is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RVPH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/13 08:17
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Reviva Pharmaceuticals Holdings, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Bruce Jackson	Benchmark Company
Jason Kolbert	D. Boral Capital LLC.

Reviva Pharmaceuticals Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 11% to US$13.50

Forecast to breakeven in 2026

Price target increased to US$14.00

Price target decreased to US$10.33

Price target decreased to US$13.00

Recent updates

Price target decreased by 11% to US$13.50

Reviva Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

Reviva Pharmaceuticals Holdings, Inc. Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 Recover Study Evaluating Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

New major risk - Financial position

Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 10, 2024

New minor risk - Profitability

Reviva Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.999852 million.

Reviva Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $9.999524 million.

New major risk - Financial position

New major risk - Share price stability

Insufficient new directors

Reviva Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

Reviva Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. announced delayed annual 10-K filing

New minor risk - Market cap size

New minor risk - Profitability

Insufficient new directors

Forecast to breakeven in 2026

Reviva Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $30.000008 million.

Reviva Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $30.000008 million.

Reviva Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $30.000008 million.

New major risk - Negative shareholders equity

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

New major risk - Share price stability

New minor risk - Market cap size

Reviva Pharmaceuticals Holdings, Inc., Annual General Meeting, Nov 13, 2023

New minor risk - Profitability

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Completion for Pivotal Phase 3 Recover Study for Brilaroxazine in Schizophrenia

New minor risk - Market cap size

Reviva Pharmaceuticals Holdings, Inc. Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Holdings, Inc. Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine

Price target increased to US$14.00

Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 Recover Study Evaluating Brilaroxazine for Schizophrenia

Reviva Pharmaceuticals Holdings, Inc., Annual General Meeting, Nov 10, 2022

Chief Financial Officer recently bought US$83k worth of stock

Reviva Pharmaceuticals drops 9% on $8.5M private placement

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Reviva Pharmaceuticals Holdings, Inc. Provides Update on Clinical Development Pipeline

Chief Financial Officer recently bought US$61k worth of stock

Reviva Pharmaceuticals Holdings, Inc. Announces Resignation of Marc Cantillon as Chief Medical Officer, Effective July 5, 2022

Reviva Pharmaceuticals Holdings, Inc. Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

Price target decreased to US$10.33

Reviva Pharmaceuticals Holdings, Inc. Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Price target decreased to US$13.00

Reviva Pharmaceuticals Holdings, Inc. Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. Announces Management Changes

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources